{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:18:03Z","timestamp":1783091883349,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.ygyno.2009.07.023","type":"journal-article","created":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T08:52:06Z","timestamp":1251363126000},"page":"215-220","source":"Crossref","is-referenced-by-count":53,"title":["A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"115","author":[{"given":"Carol","family":"Aghajanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"DeGeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Rotmensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.07.023_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/1074-5521(95)90182-5","article-title":"New insights into proteasome function: from Archaebacteria to drug development","volume":"2","author":"Goldberg","year":"1995","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ygyno.2009.07.023_bib2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin\u2013proteasome pathway is required for processing the NF-\u03baB1 precursor protein and the activation of NF-\u03baB","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2009.07.023_bib3","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1126\/science.274.5288.782","article-title":"An essential role for NF-\u03baB in preventing TNF-\u03b1-induced cell death","volume":"274","author":"Beg","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2009.07.023_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.274.5288.787","article-title":"Suppression of TNF-\u03b1-induced apoptosis by NF-\u03baB","volume":"274","author":"Van Antwerp","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2009.07.023_bib5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1126\/science.274.5288.784","article-title":"TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-\u03baB","volume":"274","author":"Wang","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2009.07.023_bib6","doi-asserted-by":"crossref","first-page":"10057","DOI":"10.1073\/pnas.94.19.10057","article-title":"Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-\u03baB control","volume":"94","author":"Chu","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2009.07.023_bib7","first-page":"219","article-title":"Adhesion molecules in tumor metastasis","volume":"4","author":"Zetter","year":"1993","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ygyno.2009.07.023_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/1074-7613(95)90030-6","article-title":"The protesome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression","volume":"2","author":"Read","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.ygyno.2009.07.023_bib9","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.070047997","article-title":"Bax degradation by the ubiquitin\/proteasome-dependent pathway: involvement in tumor survival and progression","volume":"97","author":"Benyi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2009.07.023_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","article-title":"Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts","volume":"5","author":"An","year":"1998","journal-title":"Cell Death Diff."},{"key":"10.1016\/j.ygyno.2009.07.023_bib11","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1038\/sj.onc.1202221","article-title":"Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53","volume":"17","author":"Herrmann","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2009.07.023_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2009.07.023_bib13","series-title":"Cancer: principles and practice of oncology, sixth ed. Lippincott Williams and Wilkins","first-page":"1597","article-title":"Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma","author":"Ozols","year":"2001"},{"key":"10.1016\/j.ygyno.2009.07.023_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0305-7372(03)00079-3","article-title":"Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib","volume":"29","author":"Cusack","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2009.07.023_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ygyno.2009.07.023_bib16","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.07.023_bib17","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2009.07.023_bib18","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2009.07.023_bib19","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.07.023_bib20","first-page":"841","article-title":"PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis","volume":"1","author":"Ling","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2009.07.023_bib21","doi-asserted-by":"crossref","first-page":"14671","DOI":"10.1074\/jbc.273.24.14671","article-title":"Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions","volume":"273","author":"Loo","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2009.07.023_bib22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1096\/fasebj.13.13.1724","article-title":"The human multi-drug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy","volume":"7","author":"Loo","year":"1999","journal-title":"FASEB J."},{"key":"10.1016\/j.ygyno.2009.07.023_bib23","doi-asserted-by":"crossref","first-page":"22123","DOI":"10.1074\/jbc.274.32.22123","article-title":"The proteasome, a novel protease regulated by multiple mechanisms","volume":"274","author":"DeMartino","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ygyno.2009.07.023_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"issue":"S1","key":"10.1016\/j.ygyno.2009.07.023_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.ygyno.2009.07.023_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor (Velcade \u2122 (Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ygyno.2009.07.023_bib27","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2005.16.006","article-title":"Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer","volume":"23","author":"Aghajanian","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.07.023_bib28","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/1078-0432.CCR-05-1942","article-title":"Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors","volume":"12","author":"Messersmith","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.07.023_bib29","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/1078-0432.CCR-05-1942","article-title":"A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors","volume":"12","author":"Ryan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.07.023_bib30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","article-title":"Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"24","author":"Berenson","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.07.023_bib31","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2009.07.023_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2009.07.023_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-006-0259-9","article-title":"A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies","volume":"59","author":"Ma","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2009.07.023_bib34","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1158\/1078-0432.CCR-07-0061","article-title":"A parallel dose-escalation study of weekly and twice weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors","volume":"13","author":"Voortman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2009.07.023_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00277-006-0220-3","article-title":"Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin","volume":"86","author":"Biehn","year":"2007","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ygyno.2009.07.023_bib36","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"15S","key":"10.1016\/j.ygyno.2009.07.023_bib37","first-page":"149s","article-title":"Phase II results of study PX-171-007: A phase Ib\/II study of carfilzomib (CFZ), a selective proteasomes inhibitor, in patients with selected advanced metastatic solid tumors","volume":"27","author":"Rosen","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"15S","key":"10.1016\/j.ygyno.2009.07.023_bib38","first-page":"150s","article-title":"First-in human phase I study of the novel structure proteasomes inhibitor NPI-0052","volume":"27","author":"Hamlin","year":"2009","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809005708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809005708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T20:10:21Z","timestamp":1590091821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809005708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0090825809005708"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.07.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}